NasdaqGM:PRMEBiotechs
Prime Medicine (PRME) Quarterly Loss Near US$50 Million Reinforces Bearish Community Narratives
Prime Medicine (PRME) has released fresh FY 2025 figures, with Q3 results showing total revenue of US$1.2 million and a basic EPS loss of US$0.32, as net income excluding extra items recorded a loss of US$50.6 million. The company’s quarterly revenue has moved from US$0.2 million in Q3 2024 to US$2.2 million in Q4 2024, then to US$1.5 million in Q1 2025, US$1.1 million in Q2 2025, and US$1.2 million in Q3 2025. Over the same period, basic EPS ranged between losses of US$0.32 and US$0.46 per...